| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
| ln Vitro |
In RAW264.7 cells, EtOH + LPS-induced apoptosis and mitochondrial damage are inhibited by L6H21 (10 μM, 2 hours) [1]. Attenuating EtOH + LPS-induced ROS generation and TLR4–NF-κB activation, as well as reducing NLRP3 inflammasome activation, are the effects of L6H21 (10 μM, 2 hours) [1].
|
|---|---|
| ln Vivo |
Hepatic steatosis, liver damage, and EtOH + LPS-induced hepatic fat formation are all successfully inhibited by L6H21 (10 mg/kg, oral gavage, daily) [1]. L6H21 (0-40 mg/kg, orally, daily for 4 weeks) has been demonstrated to provide neuroprotective benefits in a prediabetes model and to attenuate metabolic derangements, restore cognition, and decrease brain pathology in HFD-fed rats in a dose- and time-dependent manner[2].
|
| Cell Assay |
Apoptosis analysis [1]
Cell Types: RAW264.7 cells (mouse macrophage cell line) Tested Concentrations: 10 μM Incubation Duration: 2 hrs (hours) Experimental Results: The number of apoptotic cells was Dramatically diminished; complete inhibition of EtOH + LPS-induced Bax/Bcl -2 increase; Dramatically diminished the increase in cleaved caspase-3 protein induced by EtOH + LPS. Western Blot Analysis[1] Cell Types: RAW264.7 cells (mouse macrophage cell line) Tested Concentrations: 10 μM Incubation Duration: 2 hrs (hours) Experimental Results: EtOH + LPS-induced TLR4–NF-κB signaling is attenuated; complete inhibition of EtOH and LPS-induced increase in nuclear levels of TLR4 and NF-κB p65. Attenuate the expression of NLRP3 inflammasome induced by EtOH + LPS; inhibit the increase in NLRP3 and IL-1β protein expression; reduce the expression of p20 (an active form of caspase-1). Cell viability assay[1] Cell Types: RAW264.7 cells (mouse macrophage cell line) Tested Concentrations: 10 and 20 μM Incubation Duration: 2 hrs (hours) Experimental Results: L6H21 pretreatment prevents loss of cell viab |
| Animal Protocol |
Animal/Disease Models: Male C57BL6 mice (8-10 weeks old, n = 36, 8 mice per group, 25-30 g, containing EtOH and LPS) [1]
Doses: 10 mg/kg Route of Administration: po (oral gavage), Daily, EtOH feeding results before Route of Administration: hepatic triglyceride (TG) concentration diminished, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels Dramatically diminished; EtOH + LPS induction was Dramatically diminished Inflammation of liver tissue. Animal/Disease Models: Male Wistar rats (6-7 weeks old, 250 g, normal diet (ND) (n=8) or high-fat diet (HFD) (n=104) for 16 weeks) [2] Usage and Doses: 0, 10, 20 and 40 mg/kg Dosing: Orally one time/day for 1, 2 or 4 weeks Experimental Results: Brain mitochondrial dysfunction improved in HFD-fed rats at the 2-week dosing time point; Improves brain mitochondrial function in a dependent manner. Reduces prediabetic hippocampal cell apoptosis for 4 weeks. The reduction in dendritic spine volume and density persisted for 4 weeks. Preservation of microglial morphology in a |
| References |
|
| Molecular Formula |
C18H18O4
|
|---|---|
| Molecular Weight |
298.333125591278
|
| Exact Mass |
298.12
|
| CAS # |
24533-47-9
|
| PubChem CID |
5346378
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=CC=C(OC)C=C1)(=O)/C=C/C1=CC=CC(OC)=C1OC
|
| InChi Key |
IECVLMVZGCYCSZ-FMIVXFBMSA-N
|
| InChi Code |
InChI=1S/C18H18O4/c1-20-15-10-7-13(8-11-15)16(19)12-9-14-5-4-6-17(21-2)18(14)22-3/h4-12H,1-3H3/b12-9+
|
| Chemical Name |
(E)-3-(2,3-dimethoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3520 mL | 16.7600 mL | 33.5199 mL | |
| 5 mM | 0.6704 mL | 3.3520 mL | 6.7040 mL | |
| 10 mM | 0.3352 mL | 1.6760 mL | 3.3520 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
